The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial
Top Cited Papers
Open Access
- 17 January 2013
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 121 (3), 468-475
- https://doi.org/10.1182/blood-2012-05-429282
Abstract
NOTCH1 and SF3B1 mutations have been previously reported to have prognostic significance in chronic lymphocytic leukemia but to date they have not been validated in a prospective, controlled clinical trial. We have assessed the impact of these mutations in a cohort of 494 patients treated within the randomized phase 3 United Kingdom Leukaemia Research Fund Chronic Lymphocytic Leukemia 4 (UK LRF CCL4) trial that compared chlorambucil and fludarabine with and without cyclophosphamide in previously untreated patients. We investigated the relationship of mutations in NOTCH1 (exon 34) and SF3B1 (exon 14-16) to treatment response, survival and a panel of established biologic variables. NOTCH1 and SF3B1 mutations were found in 10% and17% of patients, respectively. NOTCH1 mutations correlated with unmutated IGHV genes, trisomy 12, high CD38/ ZAP-70 expression and were associated with reduced overall (median 54.8 vs 74.6 months, P = .02) and progression-free (median 22.0 vs 26.4 months, P = .02) survival. SF3B1 mutations were significantly associated with high CD38 expression and with shorter overall survival (median 54.3 vs 79.0 months, P < .001). Furthermore, multivariate analysis, including baseline clinical variables, treatment, and adverse prognostic factors demonstrated that although TP53 alterations remained the most informative marker of dismal survival in this cohort, NOTCH1 (HR 1.58, P = .03) and SF3B1 (HR 1.52, P = .01) mutations have added independent prognostic value.Keywords
This publication has 20 references indexed in Scilit:
- NOTCH1 mutations in CLL associated with trisomy 12Blood, 2012
- Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemiaBlood, 2012
- SF3B1and Other Novel Cancer Genes in Chronic Lymphocytic LeukemiaThe New England Journal of Medicine, 2011
- Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractorinessBlood, 2011
- Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasmsBlood, 2011
- SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implicationsLeukemia, 2011
- SomaticSF3B1Mutation in Myelodysplasia with Ring SideroblastsThe New England Journal of Medicine, 2011
- Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activationThe Journal of Experimental Medicine, 2011
- Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemiaNature, 2011
- Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic LeukemiaScience, 2004